Compare VECO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | ANIP |
|---|---|---|
| Founded | 1945 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1996 | 1999 |
| Metric | VECO | ANIP |
|---|---|---|
| Price | $30.22 | $74.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $27.25 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.1M | 324.0K |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.59 | ★ 3.32 |
| Revenue | ★ $664,294,000.00 | $206,547,000.00 |
| Revenue This Year | $18.35 | $19.88 |
| Revenue Next Year | $12.86 | $15.77 |
| P/E Ratio | $53.91 | ★ $22.77 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $16.92 | $56.71 |
| 52 Week High | $35.77 | $99.50 |
| Indicator | VECO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 39.18 |
| Support Level | $27.79 | $62.89 |
| Resistance Level | $33.48 | $85.12 |
| Average True Range (ATR) | 1.74 | 2.65 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 44.70 | 23.01 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The maximum of the company's revenue is generated from sales to the Semiconductor Industry and within China.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.